Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
The result of numerous enzymatic processes, many of which are dysregulated in pathological situations, is adenosine monophosphate [1].
|
---|---|
References |
[1]. Mondal S, et al. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions. Assay Drug Dev Technol. 2017 Oct/Nov;15(7):330-341.
|
Molecular Formula |
C10H14N5O7P
|
---|---|
Molecular Weight |
347.2212
|
CAS # |
61-19-8
|
SMILES |
P(=O)(O[H])(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)O[H])O[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~48.01 mM)
H2O : ~1.67 mg/mL (~4.81 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 3.33 mg/mL (9.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8800 mL | 14.4001 mL | 28.8002 mL | |
5 mM | 0.5760 mL | 2.8800 mL | 5.7600 mL | |
10 mM | 0.2880 mL | 1.4400 mL | 2.8800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00679250 | Completed | Drug: levocetirizine Drug: placebo to levocetirizine |
Allergic Rhinitis | Brian J Lipworth | November 2005 | Phase 4 |
NCT01939587 | Completed | Drug: PBF-680 5 mg Drug: PBF-680 20 mg |
Asthma | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
December 2013 | Phase 2 |
NCT02318043 | Completed | Drug: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg) |
Asthma | Guangzhou Institute of Respiratory Disease |
January 2007 | Not Applicable |
NCT00179010 | Terminated Has Results | Drug: Adenosine Drug: Adenosine Mono Phosphate (AMP) |
Ischemia | Vanderbilt University Medical Center | October 2003 | Phase 1 |